Adams, Paul
,
Altes, Albert
Brissot, Pierre
Butzeck, Barbara
Cabantchik, Ioav
Cançado, Rodolfo
Distante, Sonia
Evans, Patricia
Evans, Robert
Ganz, Tomas
Girelli, Domenico
Hultcrantz, Rolf
McLaren, Gordon
Marris, Ben
Milman, Nils
Nemeth, Elizabeta
Nielsen, Peter
Pineau, Brigitte
Piperno, Alberto
Porto, Graça
Prince, Dianne
Ryan, John
Sanchez, Mayka
Santos, Paulo
Swinkels, Dorine
Teixeira, Emerência
Toska, Ketil
Vanclooster, Annick
White, Desley
Article History
Received: 19 December 2017
Accepted: 8 March 2018
First Online: 27 March 2018
Compliance with ethical standards
:
: MS, PA, AP, AA, AV, BB, BM, BP, DW, DP, ET, GM, GP, KT, NM, PE, PS, RE, RC, RH, JR, and SD declare no competing financial interests. PB received fees for consulting for La Jolla and Novartis. DS received fees for consulting for “Silence therapeutics” that develop a hepcidin agonist for clinical use. DG has served as consultant (Advisory Board) for La Jolla Pharmaceutical and Silence Therapeutics, regarding possible application of hepcidin agonists for treatment of iron disorders, and also as speaker for Vifor Fresenius Medical Pharma. IC is a consultant for Hinoman Ltd on issues related to iron nutrition in green duckweed and for Aferrix, LtD on methods of detection of potentially toxic forms of iron in plasma/serum of other fluids of humans or animals. EN is a consultant La Jolla Pharmaceutical Company and Protagonist, and a scientific founder and shareholder of Intrinsic LifeSciences, companies involved in the development of diagnostics and therapies for hereditary hemochromatosis. TG is a consultant La Jolla Pharmaceutical Company, and a scientific founder and shareholder of Intrinsic LifeSciences, companies involved in the development of diagnostics and therapies for hereditary hemochromatosis.